regardless of positive clinical data, copyright's Vyndamax, a treatment for hereditary transthyretin-mediated amyloidosis (hATTR), is experiencing substantial opposition from PBMs. These insurers are typically erecting limitations to reimbursement, such as steep cost criteria and PA that limit patient opportunity. Industry indicate that the cove… Read More